 NEW YORK, March 08, 2021 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful completion and settlement of its US110 million private placement led by a strategic US investor group, that was announced on Tuesday, March 2, 2021. 